Detalhe da pesquisa
1.
Exposure-efficacy and exposure-safety analyses of ropeginterferon alfa-2b treatment in patients with polycythaemia vera.
Br J Clin Pharmacol
; 90(6): 1493-1502, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38500445
2.
A phase II trial to assess the efficacy and safety of ropeginterferon α-2b in Chinese patients with polycythemia vera.
Future Oncol
; 19(11): 753-761, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-37129584
3.
A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera.
Exp Hematol Oncol
; 12(1): 55, 2023 Jun 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-37344895
4.
[Expression of serum sHLA-G in patients with hemophagocytic syndrome and its clinical significance].
Zhongguo Shi Yan Xue Ye Xue Za Zhi
; 19(1): 219-22, 2011 Feb.
Artigo
em Zh
| MEDLINE | ID: mdl-21362256
5.
[Serum levels of tumor necrosis factor α and interferon γ in patients with hemophagocytic syndrome and its clinical significance].
Zhongguo Shi Yan Xue Ye Xue Za Zhi
; 19(6): 1505-8, 2011 Dec.
Artigo
em Zh
| MEDLINE | ID: mdl-22169313